Download PDF
Zeitschrift für Phytotherapie 2013; 34(1): 16-20
DOI: 10.1055/s-0032-1331473
Forschung
Calcium Urolithiasis
© Haug Verlag in MVS Medizinverlage Stuttgart GmbH & Co. KG

Effects of the herbal combination Canephron® N on urinary risk factors of idiopathic calcium urolithiasis in an open study

Asilbek A. Gaybullaev
1   Urology Clinic of the Postgraduate Medical Education Institute, Tashkent, Uzbekistan
,
Saidakhror S. Kariev
1   Urology Clinic of the Postgraduate Medical Education Institute, Tashkent, Uzbekistan
› Author Affiliations
Subject Editor:
Further Information

Publication History

Publication Date:
28 March 2013 (online)

    Permissions and Reprints

Zusammenfassung

Wirkungen des pflanzlichen Kombinationsarzneimittels Canephron® N auf Risikofaktoren der idiopathischen Kalziumurolithiasis in einer offenen Studie

Ziel der Studie war es, die Wirkungen von Canephron® N auf Risikofaktoren der Steinbildung zu untersuchen. Das bewährte Präparat enthält Auszüge aus Centaurii herba, Levistici radix und Rosmarini folium. Patienten mit umkomplizierter Kalziumurolithiasis wurden über 2 (n = 32) bzw. 4 Monate (n = 18) mit Canephron® N behandelt. Es resultierte ein nahezu kontinuierlicher Rückgang der Marker im Harn für die Steinbildung wie das Aktivitätsprodukt Ap[CaOx] und die Rate der Kristallurie; parallel nahmen Diurese und pH-Wert des Harns zu. Diese Parameter waren nach der 4-monatigen Therapie stärker verbessert als nach der 2-monatigen. Unerwünschte Wirkungen wurden nicht beobachtet. Wir bewerten das pflanzliche Kombinationsarzneimittel als vielversprechenden Wirkstoff für Patienten mit Risikofaktoren der idiopathischen Kalziumurolithiasis. Die Ergebnisse rechtfertigen weitere klinische Forschung.

Summary

Purpose of our study was to investigate the effects of the herbal combination Canephron® N (Bionorica SE, Germany), an approved herbal medicinal product with a fluid extract of Centaurii herba, Levistici radix and Rosmarini folium, on urinary risk factors and on the activity of stone formation in patients with urolithiasis. Patients with uncomplicated calcium urolithiasis were treated over 2 (n = 32) or 4 months (n = 18). The use of Canephron® N resulted in an almost continuous decrease of urinary markers of lithogenesis, such as Ap[CaOx] risk index and the rate of crystalluria (CU), paralleled by increases of diuresis and pH-value of urine. After 4 month therapy these parameters were even more improved than after 2 months. Adverse effects were not observed. We consider the herbal combination as a promising agent for patients with urinary risk factors of idiopathic calcium urolithiasis and encourage ongoing clinical research.

SchlÜsselwÖrter

Kalzium - Urolithiasis - Canephron® N - pflanzliches - Arzneimittel - Risikofaktoren - offene Studie

Key words

Calcium urolithiasis - Canephron® N - herbal therapy - urinary risk factors - open study
 

  • References

  • 1 Abdul-Ghani AS, El-Lati SG, Sacaan AI et al. Anticonvulsant effects of some Arab medicinal plants. Int J Crude Drug Res 1987; 25: 39-43
    PubMedSearch in Google Scholar
  • 2 Alyaev YG, Amosov AV, Grigoryan VA et al. Aphytogenicdrug Kanefron in patients with chronic cystitis and urolithiasis. Urologiia 2005; (4): 29-33
    PubMedSearch in Google Scholar
  • 3 Amosov AV, Alyaev YG, Saenko VS. Herbal drug Kanefron H in postoperative metaphylaxis of urolithiasis. Urologiia 2010; (5): 65-71
    PubMedSearch in Google Scholar
  • 4 Aqel MB. Avascular smooth muscle relaxant effect of Rosmarinus officinalis . Int J Pharmacogn 1992; 30: 281-288
    CrossrefPubMedSearch in Google Scholar
  • 5 Barsom S. Behandlung von Nierenerkrankungen. Canephron® in der urologischen Praxis. Z Allg Med 1979; 55: 997-1000
    PubMedSearch in Google Scholar
  • 6 Bauer KM, Nappert H. Klinische Erfahrungen mit Canephron bei der Behandlung von Nierenerkrankungen. Med Welt 1976; 27: 265-268
    PubMedSearch in Google Scholar
  • 7 Berger M. Die Bedeutung von Canephron® bei der Behandlung chronischer Harnwegsinfektionen. Therapiewoche 1977; 27: 1739-1742
    PubMedSearch in Google Scholar
  • 8 Berkan T, Üstünes L, Lermioglu F, Özer A. Antiinflammatory, analgesic, and antipyretic effects of an aqueous extract of Erythraea centaurium. . Planta Med 1991; 57: 34-37
    Thieme ConnectPubMedSearch in Google Scholar
  • 9 Bijarnia RK, Kaur T, Singla SK, Tandon C. A novel calcium oxalate crystal growth inhibitory protein from the seeds of Dolichos biflorus (L.). Protein J 2009; 28: 161-168
    CrossrefPubMedSearch in Google Scholar
  • 10 Butterweck V, Khan SR. Herbal medicines in the management of urolithiasis: alternative or complementary?. Planta Med 2009; 75: 1095-1103
    Thieme ConnectPubMedSearch in Google Scholar
  • 11 Chernenko VV, Savchuk VI, Zheltovska NI, Shtilvaser LM. Peculiarities in correction of urinary pH and hypercristalluria in patients. Men's Health: Ukrainian Scientific Magazine 2003; (2): 68-71
    PubMedSearch in Google Scholar
  • 12 Dallera JE, Chandhoke PS. Epidemiology and Incidence of Stone Disease. In: Stoller ML, Meng MV, eds. Current Clinical Urology, Urinary Stone Disease: The Practical Guide to Medical and Surgical Management Totowa, NJ: Humana Press Inc; 2007: 27-34
    Search in Google Scholar
  • 13 Feil G, Bichler KH, Lahme S et al. Citrate load test for detection possible disordered citrate metabolism in stone formers. Eurolithiasis. 9th European Symposium on Urolithiasis. Rotterdam, September 14-16 2001: 1-3
    PubMedSearch in Google Scholar
  • 14 Gracza L, Koch H, Löffler E. Isolierung von Rosmarinsäure aus Symphytum officinale und ihre anti-inflammmatorische Wirksamkeit in einem In-vitro-Modell. Arch Pharm 1985; 318: 1090-1095
    CrossrefPubMedSearch in Google Scholar
  • 15 Haloui M, Louedec L, Michel JB, Lyoussi B. Experimental diuretic effects of Rosmarinus offinalis and Centaurium erythraea. . J Ethnopharmacol 2000; 71: 465-472
    CrossrefPubMedSearch in Google Scholar
  • 16 Horiuchi K, Shiota S, Kuroda T et al. Potentiation of antimicrobial activity of aminoglycosides by carnosol from Salvia officinalis. . Biol Pharm Bull 2007; 30: 287-290
    CrossrefPubMedSearch in Google Scholar
  • 17 Khaskhali MH, Byer KJ, Khan SR. The effect of calcium on calcium oxalate monohydrate crystal-induced renal epithelial injury. Urol Res 2009; 37: 1-6
    CrossrefPubMedSearch in Google Scholar
  • 18 Klancnik A, Guzej B, Kolar MH et al. In vitro antimicrobial and antioxidant activity of commercial rosemary extract formulations. J Food Protect 2009; 72: 1744-1752
    PubMedSearch in Google Scholar
  • 19 Konstantinova OV. Estimation the efficiency of medicamentous methods of metaphylaxis on urolithiasis metabolic risk factors [Masters (PhD) thesis]. 2nd Moscow Medical Institute. 1990
    PubMedSearch in Google Scholar
  • 20 Kopp H Zur Behandlung von Nierenerkrankungen mit Canephron Physikal Med Rehab 1975; 16: 78-80
    PubMedSearch in Google Scholar
  • 21 Kumarasamy Y, Nahar L, Cox PJ et al. Bioac-tivity of secoiridoid glycosides from Centaurium erythraea. . Phytomedicine 2003; 10: 344-347
    CrossrefPubMedSearch in Google Scholar
  • 22 Kumarasamy Y, Nahar L, Sarker SD. Bioactivity of gentiopicroside from the aerial parts of Centaurium erythraea. . Fitoterapia 2003; 74: 151-154
    CrossrefPubMedSearch in Google Scholar
  • 23 Mounchid K, Bourjilat F, Dersi N et al. The susceptibility of Escherichia coli strains to essential oils of Rosmarinus officinalis and Eucalyptus globulus. . African J Biotechnol 2005; 4: 1175-1176
    PubMedSearch in Google Scholar
  • 24 Ochmañski W, Kmiecik J, Sułowicz W. Analysis of chemical composition of urinary stones. Int Urol Nephrol 1999; 31: 743-750
    CrossrefPubMedSearch in Google Scholar
  • 25 Pessler G, Wagner W. Die Behandlung akuter und chronischer Harnwegsinfektionen mit einem Phytopharmakon. Therapiewoche 1979; 29: 2406-2410
    PubMedSearch in Google Scholar
  • 26 Rampart M, Beetens JR, Bult H et al. Complement-dependent stimulation of prostacyclin biosynthesis: inhibition by rosmarinic acid. Biochem Pharmacol 1986; 35: 1397-1400
    CrossrefPubMedSearch in Google Scholar
  • 27 Sallis JD, Parry NF, Meehan JD et al. Controlling influence of phosphocitrate in vitro and In vivo on calcium oxalate crystal formation and growth. Scanning Microscopy 1995; 9: 127-136
    PubMedSearch in Google Scholar
  • 28 Schleicher K, Schleicher B. Klinische Erfahrungen mit Canephron® in der Frauenheilkunde, insbesondere während der Schwangerschaft. Therapiewoche 1977; 27: 9411-9413
    PubMedSearch in Google Scholar
  • 29 Schwille PO. A Survey of calcium urolithiasis in normocalcemic hypercalciuria: Possible role of nutrients and diet-mediated factors. Urol Res 1979; 7: 149-155
    PubMedSearch in Google Scholar
  • 30 Spirnak JP. Renal Calculi. In: Resnik MI, Novick AC, eds. Urology Secrets. 2nd ed. Philadelphia: Hanley & Belfus; 1999: 271-291
    Search in Google Scholar
  • 31 Sterner W, Heisler E, Popp HO, Fischer H. Studien über die Canephron-Wirkung bei chronischen Nierenerkrankungen. Physikal Med Rehab 1973; 14: 239-258
    PubMedSearch in Google Scholar
  • 32 Stoller ML, Boulton DM. Urinary Stone Disease. In: Tanago EA, McAninch JW, eds. Smith's General Urology 15th ed. New York: Lange Medical Books/McGraw-Hill; 2000: 291-320
    Search in Google Scholar
  • 33 Straub M, Strohmaier WL, Berg W et al. Diagnosis and metaphylaxis of stone disease. Consensus concept of the National Working Committee on Stone Disease for the upcoming German Urolithiasis Guideline. World J Urol 2005; 23: 309-323
    CrossrefPubMedSearch in Google Scholar
  • 34 Strohmaier WL. Volkswirtschaftliche Aspekte des Harnsteinleidens und der Harnsteinmetaphylaxe. Urologe A 2000; 39: 166-170
    CrossrefPubMedSearch in Google Scholar
  • 35 Tiselius HG, Ackermann D, Alken P et al. EAU Guidelines on urolithiasis. European Association of Urology. 2005: 1-50 http://www.uroweb.org/guidelines/
    PubMedSearch in Google Scholar
  • 36 Tiselius HG, Alken P, Buck C et al. EAU Guidelines on urolithiasis. European Association of Urology. 2009: 1-116 http://www.uroweb.org/guidelines/
    PubMedSearch in Google Scholar
  • 37 Tiselius HG. Epidemiology and medical management of stone disease. BJU Int 2003; 91: 758-967
    CrossrefPubMedSearch in Google Scholar
  • 38 Trinchieri A. Epidemiological trendsin urolithiasis: impact on our health care systems. Urol Res 2006; 34: 151-156
    CrossrefPubMedSearch in Google Scholar
  • 39 Türk C, Knoll T, Petrik A et al. EAU Guidelines on urolithiasis. European Association of Urology. 2011: 1-104 http://www.uroweb.org/guidelines/
    PubMedSearch in Google Scholar
  • 40 Valentao P, Fernandes E, Carvalho F et al. Hydroxyl radical and hypochlorous acid scavenging activity of small centaury (Centaurium erythraea) infusion. A comparative study with green tea (Camellia sinensis). Phytomedicine 2003; 10: 517-522
    CrossrefPubMedSearch in Google Scholar
  • 41 Williams G, Sallis JD. Structural factors influencing the ability of compounds to inhibit hydroxyapatite formation. Calcif Tissue Int 1982; 34: 169-177
    CrossrefPubMedSearch in Google Scholar
  • 42 Wittenberger R, Naber K. Therapie des chronisch-rezidivierenden Harnwegsinfektes mit Phytotherapeutika. Therapiewoche 1980; 30: 4269-4279
    PubMedSearch in Google Scholar
  • 43 Yamahara J, Konoshima T, Sawada T, Fujimura H. Biologically active principles of crude drugs: pharmacological actions of Swertia japonica extracts, swertiamarine and gentianine. Yakugaku Zasshi 1978; 98: 1446-1451
    PubMedSearch in Google Scholar
  • 44 Yarnell E. Botanical medicines for the urinary tract. World J Urol 2002; 20: 285-293
    PubMedSearch in Google Scholar
  • 45 Yeni E, Unal D, Verit A et al. The cost of diagnosis in patients with urolithiasis. Urolithiasis. 2nd EULIS Meeting (10th European Symposium on Urolithiasis). Istanbul 2003; 348
    PubMedSearch in Google Scholar